100 AML Flashcards
Most common acute leukemia in older patients
AML
Mean age at diagnosis of AML
67 years
True or false. Most cases of AML are due to radiation exposure
False. Most cases of AML are idiopathic
Germline mutations associated with increased risk for developing myeloid neoplasm
CEBPA, DDX41 RUNX1 ANKRD26 ETV6 GATA2
True or false. Somatic cell chromosome aneuploidy such as Downs Syndrome with Trisomy 21 is associated with increased incidence of AML
True
Down syndrome associated AML is typically what subtype and is associated with mutation in what gene?
Acute megakaryocytic subtype and is associated with mutation in the GATA1 gene
Another disorder that may evolve into AML that is due to mutations in the genes encoding the granulocyte colony stimulating factor receptor and neutrophil elastase
Congenital neutropenia or Kostmann syndrome
Leading cause of therapy associated AML?
Anticancer drugs
This anticancer agent is associated AML occurs 1-3 year after exposure. What genetic abberations are noted?
Topoisomerase II inhibitors associated with leukemia 1-3 years after exposure and shows abberations in chromosome 11q23
What other exposures result in home marrow failure that may later involved into AML
Ionizing radiation
Benzene
Chloramphenicol
Phenylbutazone
This agent is associated with AML 4-6 years after exposure and what is the associated with aberrations
Ankylating agents; abberations in chromosome 5 and 7
Required to esbtalish the diagnosis of AML
Marrow or blood blast count of more than 20%
Diagnosis of Acute myeloid leukemia is based on the presents of this genetic findings
PML- RARA fusion product
Fusion products associated with core binding factor AML
Fusion products RUNX1- RUNX1T1 and CBFB-MYH11
Important in many cellular processes including cell growth control, apoptosis and senescene
PML
This gene encodes a number of nuclear hormone receptor family of transcription factors
RARA gene
This fusion gene suppresses gene transcription and block differentiation beyond promyelocyte stage
PML RARA
Provide the most important independent prognostic information on AML
Chromosome finding
AML with this genetic charteristic is associated with very good prpgnosis
t(15;17) - - 85% cured
t(8;21) - - 55% cured
Inv(16)
No cytogenetic abnormality - - 40% cured
AML with this cytogenetic property is associated with very poor prognosis
Complex karyotype
t(6;9)
Inv(3)
-7
True or false. Overexpresion of miR-155 and miR-3151 predicts unfavorable outcomes in AML. Which overexpression predicts favorable outcome?
True
Favorable outcome: miR-181a
One of the most important risk factor for AML
Age. Advancing age poor prognosis
True or false. 85% of APL can achieve long term survival if treated with ATRA and may not need bone marrow transplantation.
True
Why is advanced age associated with poor prognosis?
- Influence on the ability to survive induction therapy due to coexisting medical comorbidities
- Each successive decade of age, a greater portion have intrinsically more resistant disease
Clinical feature associated with lower complete remission rate and shorter survival time
Cytopenia
True or false. Complete Remission is higher in patients who had anemia, leukopenia, and thrombocytopenia for more than 3 months before diagnosis of AML
False. Cytopenia is associated with lower complete remission in patients with AML
True or false. Among patients with hyperleukocytosis (more than 100,000/ uL), early CNS bleeding and pulmonary leukostasis contribute to poor outcomes
True
Define complete remission
On peripheral blood Neutrophil count more than 1,000 Platelet count more than 1,000 Absent circulating blasts On bone marrow Less than 5% blasts Absent Auer rods
First symptoms among AML patients
Fatigue
Fever with or without identifiable cause is the is the initial presentation in patients for how many percent
10%
Tumor mass consisting of myeloid blasts occurring at anatomic sites other than bone marrow
Myeloid sarcoma
Common sites for myeloid sarcoma
Skin Lymph mode GIT Soft tissue Testis
True or false. Patients with myeloid sarcoma is associated with chromosome aberrations
True
What time of leukemia is hemorrhagic complications common?
Acute promyelocytic leukemia
Infiltration of the gingiva, skin, soft tissues, or meninges with leukemic blasts is characteristics of what?
Mklonocytic subtypes and those with 11q23 chromosomal abnormalities
Hematologic findings usually present at diagnosis
Anemia
Median Leukocyte count in patient with AML
Median presenting Leukocyte count is about 15,000/ uL
Only 20% have counts more than 100,000 u/L
Two phases in the treatment of AML
Induction
Post remission management
Common used regimen in induction
Cytarabine + anthracycline 7+3
Cytarabine for 7 days and anthracycline day 1, 2 and 3
Cell cycle S phase specific antimetabolite that becomes phosphorylated intracellularly to an active triphosphate firm that interferes with DNA synthesis
Cytarabine
Anthracycline used in AML
Daunorubicin
Idarubicin
True or false. Post remission therapy is designed to eradicate residual leukemic cells to prevent relapse and prolong survival
True
Best relapse prevention strategy currently available for AML
Allogeneic HCT
True or false. Relapsed AML is typically resistant to chemotherapy
True
Favored strategy for AML in CR1
Allogeneic HCT
Diagnosed. AML. Favorable risk . Induction therapy done. If complete remission,
Intermediate dose cytarabine (1-1.5 g/m2)
Induction therapy dose for cytarabine is 60-90 mg/kg
Diagnosed. AML. Intermediate risk . Induction therapy done. If complete remission,
Allogeneic HCT–preferres
Autologous Hct if less than 60 yrs old
Intermediate dose cytarabine
Diagnosed. AML. Adverse risk . Induction therapy done. If complete remission,
Allogeneic HCT
Alternative: donor transplant if no HLA matched donor
Diagnosed. AML. Refractory/ Relapse. What next?
Salvage therapy
Yes suitable donor: allogeneic HCT
No suitable donor: autologous HCT
Target platelet count in AML? Target Hgb?
Platelet count more than 10,000/ uL
Hgb more 7 g/dL
Acceptable regimens for empiric treatment of infection in neutropenic AML
Imipenem-cilastin Meropenem Piperacillin tazobactam Cefepime Ceftazidime
Antifungal treatment for fever that persists for 4-7 days
Caspofungin
Voriconazole
Isavuconazoniun
Liposomal amphothericin B
Predictive of response to salvage therapy
Length of first complete remission
True or false. Patient with complete remission more than 12 months have a higher change of attaining CR2.
True
True or false. APL is highly curable and 85% achieve long term survival with current approaches
True
Oral drug that induces differentiation of leukemic cells bearing t(15;17) where disruption of RARA gene encoding a retinoid acid receptor occurs
Tretinoin (ATRA)
What is the complication of ATRA?
APL differentiation syndrome
When does APL syndrome occur and how does it manifest
APL syndrome occurs during the first 3 weeks of treatment and characterized by fever, fluid retention, dyspnea, chest pain, pulmonary infiltrates, pericarditis effusion and hypoxemia.
What is the pathophysiology of APL?
Adhesion of differentiated neoplastic cells to pulmonary vasculature endothelium
How is APL managed?
Glucocorticoids
Chemotherapy
Support measures
Discontinuation of ATRA in severe cases of APL
Standard of care for APL
ATRA + ATO (arsenic trioxide)
True or false. ATRA + ATO is Inferior to ATRA+ idarubicin
False. ATRA + ATO is superior and thus the standard
Signal associated with long term disease free survival
Absent PML RARA by RT PCR
Standard of post remission monitoring of APL
Sequential monitoring of PML RARA by RT PCR
Remains the preferred reinduction therapy for relapsed patient
ATO
What the next step in CR2 in patients with RT PCR negative status? To those who remain positive on RT PCR
Negative: Autologous HCT
Positive: allogeneic HCT
Bears the retinoid acid receptor
t(15;17)
Associated with myeloid sarcoma
t(8;21)
Important in distinguishing AML from ALL and other subtypes of AML
BMA with phenotyping
Character of complete remission in AML except A. Platelet count more than 100,000 B. Neutrophil count 1000 C. Blast less than 5% D. Hemoglobin more than 100 g/L
A. Platelet count more than 100,000
B. Neutrophil count 1000
C. Blast less than 5%
D. Hemoglobin more than 100 g/L–> Hemoglobin is not considered in determining complete remission
Remain the major cause of Morbidity and death during induction post remission therapy in AML
Infection